Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion

In Vivo

Volumn 16, Issue 5, 2002, Pages 361-363

  Syrigos, Konstantinos N ^a   Michalaki, Vicky ^a   Mitromaras, Athanasios ^a   Pliarchopoulou, Fani ^a   Katirtzoglou, Nikolaos ^a   Antonaki, Eleftheria ^a   Roussou, Paraskevi ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Bisphosphonates; Bone metastasis; Ibandronate

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANALGESIC AGENT; CALCIUM; CREATININE; IBANDRONIC ACID; PHOSPHATE; PHOSPHONIC ACID DERIVATIVE; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYTICAL PARAMETERS; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; BONE LESION; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONVALESCENCE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DAY CARE; DISEASE ACTIVITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG FEVER; DRUG INFUSION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERCALCEMIA; LEUKOPENIA; LYMPHOCYTE DEPLETION; MALE; MULTIPLE MYELOMA; PHOSPHATE BLOOD LEVEL; PROSTATE CANCER; SIDE EFFECT; STATISTICAL SIGNIFICANCE; UREA NITROGEN BLOOD LEVEL; BLOOD; BONE TUMOR; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; OSTEOLYSIS;

ADULT; AGED; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE RESORPTION; CALCIUM; DIPHOSPHONATES; FEMALE; HUMANS; HYPERCALCEMIA; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PHOSPHATES;

EID: 0036762536     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Parfitt AM, Mundy GR, Roodman GD, Hughes DE and Boyce B: A new model for the regulation of bone resorption with particular reference to the effects of bisphosphonates. J Bone Miner Res 11(2): 150-9, 1996.
2. Galasko CSB: The anatomy and pathways of skeletal metastases. Hall, Boston pp 49-63, 1981.
3. Bounameaux HM, Schifferli J, Montani JP, Junk A and Chatelanat F: Renal failure associated with intravenous bisphosphonates. Lancet 471: 1281, 1983.
4. Sawyer N, Newstead C, Drummond A and Cunningham J: Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene-APD) as single shot treatment of hypercalcaemia. Bone Miner 9: 128-138, 1990.
5. Pecherstorfer M, Hermann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thurlimann B, Tubiana-Hulin M, Steinhauer EU, Van Eijkeren M, Huss HJ and Thiebaud D: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcaemia of malignancy. J Clin Oncol 14: 268-276, 1996.
6. Muhlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K and Fleisch H: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6: 1003-1011, 1991.
7. Zojer N, Keck AV and Pecherstorfer M: Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Safety 21(5): 389-406, 1999.
8. Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ and Body JJ: Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 11(5): 587-93, 1996.
9. Berenson JR: Skeletal metastases/hypercalcaemia. Classic Papers and Current Comments 4: 387-393, 1999.
10. Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR and Schoter KH: Three-monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103: 298-307, 1997.
11. Tortoriello A, Pacelli R, Procaccini E, Frattolillo A, Turito G, Iodice P, Varriale E, Mazzano N, La Provitera A, Libutti M, Silvestro P, Bruni G, Ferrari E, Iannielo G, Cigolari S, Carteni G, Barbarisi A and Iaffaioli RV: Letrozole + pamidronate + goserelin + docetaxel + radiotherapy in the treatment of bone metastasis by breast cancer. Preliminary data of a phase II study. Proc ASCO 20: 1983A, 2001.